세계의 중추신경계 바이오마커 시장 보고서(2025년)

Central nervous system (CNS) biomarkers are specific substances or measurable indicators within the CNS that offer insights into normal functioning, disease processes, or responses to treatments. They play a crucial role in diagnosing or predicting neurological disorders, monitoring disease progression, and anticipating responses to drug therapy.

The primary categories of CNS biomarkers include safety biomarkers, efficacy biomarkers, validation biomarkers, and others. Safety biomarkers encompass measurable biological parameters or indicators employed to evaluate the safety of drugs, medical interventions, or environmental exposures. They find application in treating various diseases such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and more, contributing to drug discovery and development, personalized medicines, disease risk assessment, diagnostics, among other areas. Diverse end-users, such as diagnostic labs, clinics, hospitals, research centers, and others, utilize these biomarkers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides central nervous system biomarkers market statistics, including central nervous system biomarkers industry global market size, regional shares, competitors with a central nervous system biomarkers market share, detailed central nervous system biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. This central nervous system biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system biomarkers market size has grown strongly in recent years. It will grow from $5.58 billion in 2024 to $6.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population.

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $8.98 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

The forecast of 10.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neurology research by driving up the cost of CSF collection systems and tau protein assays sourced from Sweden and Australia, exacerbating Alzheimer's diagnostic costs and delaying neurodegenerative disease research. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated increase in neurological illnesses is expected to drive the expansion of the central nervous system biomarker market in the future. Neurological illnesses, also referred to as neurological disorders, encompass a broad spectrum of conditions affecting the brain, spinal cord, and nerves throughout the body. These disorders can result from various factors, including genetic influences, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In the realm of neurological disorders, central nervous system (CNS) biomarkers play a crucial role in clinical diagnosis, determining illness risk or prognosis, assessing disease stage, and monitoring treatment response. They contribute significantly to comprehending these diseases and their treatability. For instance, in April 2023, the Centers for Disease Control and Prevention, a US government agency, reported that Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older, with projections indicating a tripling of this number to 14 million by 2060. Furthermore, the incidence of the disease is observed to double every five years after the age of 65. Consequently, the surge in neurological illnesses is a key factor propelling the growth of the central nervous system biomarker market.

The growing prevalence of obesity is expected to fuel the expansion of the central nervous system biomarker market in the coming years. Obesity, a medical condition marked by an excess of body fat, can adversely affect an individual's health. Central nervous system biomarkers are employed to study obesity, aiding in the understanding of the neurological mechanisms that control body weight and eating behavior, as well as in the development of effective anti-obesity treatments. For example, in March 2023, the World Heart Foundation, a Switzerland-based global cardiovascular organization, reported that approximately 2.3 billion adults and children worldwide are either obese or overweight. With current obesity trends, it is projected that the number of people affected by obesity will rise to 2.7 billion by 2025. Thus, the increasing prevalence of obesity is driving the growth of the central nervous system biomarker market.

A prominent trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Leading companies in the market are dedicated to developing groundbreaking drugs and obtaining approvals to enhance their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, disclosed the approval and authorization of its investigational new drug (IND) application for DB104 (liafensine) by the US Food and Drug Administration (FDA) for treating treatment-resistant depression (TRD). This marks the initiation of the first biomarker-guided global CNS clinical trial for TRD. The drug has the potential to identify patients more likely to respond to liafensine, facilitating more personalized treatment decisions. Liafensine, a novel compound, functions by elevating levels of dopamine and norepinephrine in the brain.

Major players in the central nervous system biomarker market are strategically focused on introducing advanced solutions, such as assay kits. An assay kit is a pre-packaged set of reagents and materials utilized for a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a research and development company based in Japan, launched an Automated Immunoassay System. This assay kit is designed to detect amyloid beta (AB) accumulation in the brain, a contributor to Alzheimer's disease, using a small blood sample. The kit measures the ratio of AB peptides in the blood through an automated immunoassay system. This facilitates clinicians in identifying AB accumulation in the brain with a minimal blood sample, enabling earlier diagnosis and treatment for patients.

In June 2022, Fujirebio Holdings Inc., a biotechnology company based in Japan, acquired ADx NeuroSciences for approximately $43 million (40 million euros). This acquisition aims to broaden Fujirebio Holdings' portfolio of central nervous system biomarkers, leverage ADx NeuroSciences' expertise and technology, and enhance its global presence in the central nervous system biomarker market. ADx NeuroSciences, headquartered in Belgium, is a biomarker-assay company specializing in the development and production of biomarkers for central nervous system (CNS) disorders.

Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics

North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central nervous system biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Safety Biomarker; Efficacy Biomarker; Validation Biomarker; Other Types
• 2) By Disease: Multiple Sclerosis; Alzheimer's Disease; Parkinson's Disease; Traumatic Brain Injury; Other Diseases
• 3) By Application: Drug Discovery And Development; Personalized Medicines; Disease Risk Assessment; Diagnostics; Other Applications
• 4) By End-Users: Diagnostic Labs; Clinics; Hospitals; Research Centers; Other End-Users
• Subsegments:
• 1) By Safety Biomarker: Toxicity Biomarkers; Adverse Event Biomarkers
• 2) By Efficacy Biomarker: Pharmacodynamic Biomarkers; Response Biomarkers
• 3) By Validation Biomarker: Predictive Biomarkers; Prognostic Biomarkers
• 4) By Other Types: Diagnostic Biomarkers; Biomarkers For Disease Progression
• Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Siemens Healthineers; Thermo Fisher Scientific Inc; Abbott Laboratories; Merck KGaA; Eurofins Scientific; Charles River Laboratories International Inc.; PerkinElmer Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Axon Neuroscience SE; Alector Inc.; Oryzon Genomics S.A.; Abastar Mdx Inc.; Banyan Biomarkers Inc.; Avacta Group PLC; Geno Technology Inc.; Anavex Life Sciences Corp.; Alseres Pharmaceuticals Inc.; Aposense Ltd.; Applied Neurosolutions Inc.; C2N Diagnostics; Alzheon Inc.; DiaGenic ASA; Abiant Inc.; Avid Radiopharmaceuticals Inc.; Acumen Pharmaceuticals Inc.; Cassava Sciences Inc.; Denali Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Central Nervous System Biomarkers Market Characteristics

3. Central Nervous System Biomarkers Market Trends And Strategies

4. Central Nervous System Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Central Nervous System Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Central Nervous System Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Central Nervous System Biomarkers Market Growth Rate Analysis
• 5.4. Global Central Nervous System Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Central Nervous System Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Central Nervous System Biomarkers Total Addressable Market (TAM)

6. Central Nervous System Biomarkers Market Segmentation

• 6.1. Global Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Safety Biomarker
• Efficacy Biomarker
• Validation Biomarker
• Other Types
• 6.2. Global Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis
• Alzheimer's Disease
• Parkinson's Disease
• Traumatic Brain Injury
• Other Diseases
• 6.3. Global Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Discovery And Development
• Personalized Medicines
• Disease Risk Assessment
• Diagnostics
• Other Applications
• 6.4. Global Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Labs
• Clinics
• Hospitals
• Research Centers
• Other End-Users
• 6.5. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Safety Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Toxicity Biomarkers
• Adverse Event Biomarkers
• 6.6. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Efficacy Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacodynamic Biomarkers
• Response Biomarkers
• 6.7. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Validation Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Predictive Biomarkers
• Prognostic Biomarkers
• 6.8. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Biomarkers
• Biomarkers For Disease Progression

7. Central Nervous System Biomarkers Market Regional And Country Analysis

• 7.1. Global Central Nervous System Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Central Nervous System Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Central Nervous System Biomarkers Market

• 8.1. Asia-Pacific Central Nervous System Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Central Nervous System Biomarkers Market

• 9.1. China Central Nervous System Biomarkers Market Overview
• 9.2. China Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Central Nervous System Biomarkers Market

• 10.1. India Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Central Nervous System Biomarkers Market

• 11.1. Japan Central Nervous System Biomarkers Market Overview
• 11.2. Japan Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Central Nervous System Biomarkers Market

• 12.1. Australia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Central Nervous System Biomarkers Market

• 13.1. Indonesia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Central Nervous System Biomarkers Market

• 14.1. South Korea Central Nervous System Biomarkers Market Overview
• 14.2. South Korea Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Central Nervous System Biomarkers Market

• 15.1. Western Europe Central Nervous System Biomarkers Market Overview
• 15.2. Western Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Central Nervous System Biomarkers Market

• 16.1. UK Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Central Nervous System Biomarkers Market

• 17.1. Germany Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Central Nervous System Biomarkers Market

• 18.1. France Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Central Nervous System Biomarkers Market

• 19.1. Italy Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Central Nervous System Biomarkers Market

• 20.1. Spain Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Central Nervous System Biomarkers Market

• 21.1. Eastern Europe Central Nervous System Biomarkers Market Overview
• 21.2. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Central Nervous System Biomarkers Market

• 22.1. Russia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Central Nervous System Biomarkers Market

• 23.1. North America Central Nervous System Biomarkers Market Overview
• 23.2. North America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Central Nervous System Biomarkers Market

• 24.1. USA Central Nervous System Biomarkers Market Overview
• 24.2. USA Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Central Nervous System Biomarkers Market

• 25.1. Canada Central Nervous System Biomarkers Market Overview
• 25.2. Canada Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Central Nervous System Biomarkers Market

• 26.1. South America Central Nervous System Biomarkers Market Overview
• 26.2. South America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Central Nervous System Biomarkers Market

• 27.1. Brazil Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Central Nervous System Biomarkers Market

• 28.1. Middle East Central Nervous System Biomarkers Market Overview
• 28.2. Middle East Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Central Nervous System Biomarkers Market

• 29.1. Africa Central Nervous System Biomarkers Market Overview
• 29.2. Africa Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Central Nervous System Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Central Nervous System Biomarkers Market Competitive Landscape
• 30.2. Central Nervous System Biomarkers Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Central Nervous System Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Eurofins Scientific
• 31.3. Charles River Laboratories International Inc.
• 31.4. PerkinElmer Inc.
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. QIAGEN N.V.
• 31.7. Axon Neuroscience SE
• 31.8. Alector Inc.
• 31.9. Oryzon Genomics S.A.
• 31.10. Abastar Mdx Inc.
• 31.11. Banyan Biomarkers Inc.
• 31.12. Avacta Group PLC
• 31.13. Geno Technology Inc.
• 31.14. Anavex Life Sciences Corp.
• 31.15. Alseres Pharmaceuticals Inc.

32. Global Central Nervous System Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System Biomarkers Market

34. Recent Developments In The Central Nervous System Biomarkers Market

35. Central Nervous System Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Central Nervous System Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Central Nervous System Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Central Nervous System Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer